

AMENDMENTS TO THE CLAIMS

Claims 1-7 (Withdrawn)

Claims 8-10 (Canceled)

Claims 11-16 (Withdrawn)

Claims 17-22 (Canceled)

Claims 23-30 (Withdrawn)

31. (New) A transgenic mouse whose genome comprises a disruption in an endogenous chemokine receptor 9A gene, wherein where the disruption is homozygous, the transgenic mouse exhibits decreased agility, coordination or balance, relative to a wild-type mouse.

32. (New) The transgenic mouse of claim 31, wherein the decreased agility, coordination or balance comprises decreased performance on an accelerating rotarod, when compared to a wild-type mouse.

33. (New) The transgenic mouse of claim 32, wherein the decreased performance is characterized by falling from an accelerating rotarod at lower speeds relative to a wild-type mouse.

34. (New) A cell obtained from the transgenic mouse of claim 31.

35. (New) A transgenic mouse comprising a heterozygous disruption in an endogenous chemokine receptor 9A gene, wherein the disruption in a homozygous state results in a transgenic mouse exhibiting decreased agility, coordination or balance, relative to a wild-type mouse.

36. (New) The transgenic mouse of claim 35, wherein the decreased agility, coordination or balance comprises decreased performance on an accelerating rotarod, when compared to a wild-type mouse.

37. (New) The transgenic mouse of claim 36, wherein the decreased performance is characterized by falling from an accelerating rotarod at lower speeds relative to a wild-type mouse.

38. (New) A method of producing a transgenic mouse comprising a disruption in an endogenous chemokine receptor 9A gene, the method comprising:

- a) providing a murine embryonic stem cell comprising a disruption in an endogenous chemokine receptor 9A gene;

- b) introducing the murine embryonic stem cell into a blastocyst;
 - c) implanting the resulting blastocyst into a pseudopregnant mouse, wherein said pseudopregnant mouse gives birth to a chimeric mouse; and
 - d) breeding the chimeric mouse to produce the transgenic mouse comprising a disruption in the endogenous chemokine receptor 9A gene;
wherein where the disruption is homozygous, the transgenic mouse exhibits decreased agility, coordination or balance, relative to a wild-type mouse
39. (New) The transgenic mouse produced by the method of claim 38.